Last reviewed · How we verify
Balversa
At a glance
| Generic name | Balversa |
|---|---|
| Sponsor | xCures |
| Target | Fibroblast growth factor receptor 1, Fibroblast growth factor receptor 2, Fibroblast growth factor receptor 3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
| Annual revenue | 300 |
Approved indications
- Metastatic urothelial carcinoma
Common side effects
Key clinical trials
- Erdafitinib Plus Abiraterone Acetate or Enzalutamide in Double Negative Prostate Cancer (Phase 2)
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol (Phase 2)
- Erdafitinib in Metastatic Steroid-cell Tumor of the Ovary, NOS (NA)
- A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers Wit (Phase 2)
- A Phase II Clinical Study on Precision Treatment of Rare Tumours in China Guided by Patient-Derived Tumor Organoids (PDO) and Next-Generation Sequencing (NGS) (Phase 2)
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations (Phase 2)
- Molecular Analysis for Therapy Choice (MATCH) (Phase 2)
- MATCH Treatment Subprotocol K1: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients With Tumors With FGFR Amplifications (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |